Flare Therapeutics Inc., a leader in biotechnology focusing on transcription factors for precision medicine, has named Douglas Manion, M.D., FRCP (C) as Chief Executive Officer, effective immediately. Dr. Manion, with an extensive background in pharmaceutical research and development, steps into the leadership role previously held on an interim basis by Abbie Celniker, Ph.D. Dr. Celniker, a partner at Third Rock Ventures, will continue her involvement as Chair of the Board of Directors.
“I am delighted to welcome Doug to FlareTx and want to express my deepest confidence in his ability to lead the company during this next stage of growth. Over the course of his career, he has gained substantial company building and drug development expertise, which will be invaluable as FlareTx continues to grow as an organization and advances its clinical-stage pipeline and capabilities in drugging transcription factors,” said Dr. Celniker.
“There has been rapid growth at FlareTx since the company was launched and I am excited for this opportunity to lead such an exceptional and cross-functional team as we advance FX-909 toward clinical proof of concept data in the second half of this year and fully recognize the potential of our discovery engine as we seek to change the paradigm in drugging transcription factors,” said Dr. Manion.
Dr. Manion joins Flare Therapeutics from Aclaris Therapeutics, Inc., where he was President and CEO. Prior to that, he held a pivotal role at Arena Pharmaceuticals, Inc. and has been a key figure in drug development at several leading pharmaceutical companies, including Bristol-Myers Squibb and GlaxoSmithKline.
About Flare Therapeutics Inc.: Located in Cambridge, Massachusetts, Flare Therapeutics is dedicated to pioneering the discovery of precision medicines targeting transcription factors, a previously challenging area of drug development. Leveraging a proprietary discovery engine, Flare Therapeutics is advancing a pipeline of novel therapies, including FX-909, aimed at transforming treatment paradigms in cancer and other serious diseases. With a focus on genetic and biochemical mechanisms, Flare’s approach could herald a new era in the therapeutic modulation of transcription factors.
Also Read : Performance Management or Perception Management?
